(Q45789815)

16 December 2017

title

Interferon antibodies in patients with chronic hepatitic C virus infection treated with recombinant interferon alpha-2 alpha (English)

1 reference

16 December 2017

ORCID Public Data File 2021

1 reference

1 reference

author name string

P Bonetti

1

1 reference

16 December 2017

G Diodati

2

1 reference

16 December 2017

C Drago

3

1 reference

16 December 2017

C Casarin

4

1 reference

16 December 2017

S Scaccabarozzi

5

1 reference

16 December 2017

G Realdi

6

1 reference

16 December 2017

A Ruol

7

1 reference

16 December 2017

A Alberti

8

1 reference

16 December 2017

language of work or name

1 reference

1 March 1994

1 reference

16 December 2017

published in

Journal of Hepatology

1 reference

16 December 2017

volume

20

1 reference

16 December 2017

issue

3

1 reference

16 December 2017

page(s)

416-420

1 reference

16 December 2017

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2894%2980018-9

7 January 2021

Randomised controlled trial of interferon alfa (lymphoblastoid interferon) in chronic non-A non-B hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2894%2980018-9

7 January 2021

A randomized controlled open study of interferon alpha-2b treatment of chronic non-A, non-B posttransfusion hepatitis: no correlation of outcome to presence of hepatitis C virus antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2894%2980018-9

7 January 2021

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2894%2980018-9

7 January 2021

The biological basis for clinical use of interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2894%2980018-9

7 January 2021

Recombinant human interferon alfa-2a in community-acquired non-A, non-B chronic active hepatitis. Preliminary results of a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2894%2980018-9

7 January 2021

Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2894%2980018-9

7 January 2021

The detection of antibodies to recombinant interferon alfa-2a in human serum

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2894%2980018-9

7 January 2021

Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon alfa-2a by intramuscular injection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2894%2980018-9

7 January 2021

Resistance to Recombinant Interferon Alfa-2a in Hairy-Cell Leukemia Associated with Neutralizing Anti-Interferon Antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2894%2980018-9

7 January 2021

Clinical significance of anti-IFN-alpha antibody titres during interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2894%2980018-9

7 January 2021

Leucocyte-derived interferon-alpha in patients with antibodies to recombinant IFN-alpha 2b

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2894%2980018-9

7 January 2021

Interferon antibodies in patients with chronic HBV infection treated with recombinant interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2894%2980018-9

7 January 2021

10.1016/S0168-8278(94)80018-9

Identifiers

DOI

1 reference

16 December 2017

1 reference

16 December 2017